Tactile Systems Technology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TCMD research report →
Range $35 – $35
Price Chart
About the company
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema.
- CEO
- Sheri Louise Dodd
- IPO
- 2016
- Employees
- 1,086
- HQ
- Minneapolis, MN, US
Get TickerSpark's AI analysis on TCMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $573.48M
- P/E
- 24.38
- Fwd P/E
- 22.66
- PEG
- 0.67
- P/S
- 1.61
- P/B
- 2.55
- EV/EBITDA
- 12.14
- Div Yield
- 0.00%
- Gross Margin
- 74.32%
- Op Margin
- 9.46%
- Net Margin
- 6.68%
- ROE
- 10.73%
- ROIC
- 9.02%
Latest fiscal year · YoY change
- Revenue
- $329.52M+12.5%
- Gross Profit
- $247.70M+14.3%
- Op Income
- $29.28M
- Net Income
- $19.09M+12.5%
- EPS
- $0.83+16.9%
- OCF Growth
- +5.3%
- FCF Growth
- +6.0%
- 52W High
- $37.77
- 52W Low
- $20.53
- 50D MA
- $23.76
- 200D MA
- $25.64
- Beta
- 0.89
- RSI (14)
- 53
- Avg Volume
- 248.63K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Tactile Medical delivered 13% lymphedema growth and higher EBITDA guidance, while airway clearance remained pressured by DME inventory digestion.· November 2, 2026
- Total revenue was $91.9 million, up 7.1% year over year, driven by lymphedema growth that offset a decline in airway clearance.
- Lymphedema revenue rose 13.1% to $81.8 million, marking the fifth straight quarter of above-market double-digit growth.
- Gross margin expanded to 76.7% from 75.8%, and adjusted EBITDA was $14.3 million, with full-year EBITDA guidance raised to $50 million to $52 million.
- Airway clearance revenue fell 25.1% to $10 million as DME customers worked through excess inventory tied to the next-gen AffloVest launch.
- Management reiterated confidence in 2027 and beyond, citing LymphaTech, Flexitouch Pro, payer wins in head and neck, and a more scalable operating model.
Third quarter total revenue was $91.9 million, up $6.1 million or 7.1% year over year. Lymphedema revenue increased 13.1% to $81.8 million, with Medicare revenue up approximately 11% and commercial revenue up approximately 17%, while airway clearance revenue decreased 25.1% to $10 million. Gross margin expanded to 76.7% from 75.8% a year ago, operating income was $9.6 million versus $11 million, net income was $7.2 million or $0.31 per diluted share versus $8.2 million or $0.36, and adjusted EBITDA was $14.3 million versus $14.4 million. Year to date, total revenue was $252.8 million and adjusted EBITDA was $29.5 million, up approximately 35%. For full year 2026, management maintained revenue guidance of $360 million to $366 million, expects GAAP gross margin of approximately 76.5%, and raised adjusted EBITDA guidance to $50 million to $52 million. Airway clearance is now expected to decline mid- to high single digits for the full year, while lymphedema is still expected to grow in the low double digits. Management expects sequential improvement in Q4 revenue, especially in lymphedema and airway clearance, but noted Q4 lymphedema growth will be moderated by a tough comparison.
Sheri Dodd struck an upbeat but measured tone, emphasizing that the quarter reinforced the durability of the core lymphedema business. She highlighted progress on three strategic priorities: expanding access to care through diagnostics and payer work, improving conversion from referral to shipment, and broadening treatment options through innovation. She also stressed that 2027 should not be viewed as a hockey-stick year, saying growth should be durable and steady rather than sudden, even with upcoming product and diagnostic catalysts.
Elaine Birkemeyer focused on the financial execution: revenue of $91.9 million, gross margin of 76.7%, operating income of $9.6 million, net income of $7.2 million, and adjusted EBITDA of $14.3 million. She said operating expenses rose to $60.9 million, mainly from the annualization of prior-year sales hiring and continued technology investment, but year-to-date adjusted EBITDA still increased about 35% to $29.5 million. She also noted the balance sheet ended with $75.1 million in cash and no borrowings, generated $12 million in operating cash flow, and had about $12.5 million remaining under the $25 million share repurchase authorization. Capital allocation priorities remain organic investment, disciplined M&A capacity, and buybacks when appropriate.
Analysts focused heavily on 2027, asking whether lymphedema could accelerate further and whether airway clearance inventory issues might resolve. Management said they see no reason for lymphedema to slow, but cautioned that diagnostics, referrals, documentation and reimbursement changes take time, so they do not expect a sudden step-up. On airway clearance, Sheri Dodd said the slowdown is concentrated in a few DMEs still burning through excess inventory, with no change in patient demand or competition. Management also said Flexitouch Pro should not change reimbursement or gross margin meaningfully, and that payer changes in head and neck lymphedema are real but gradual, with no near-term revenue hockey stick.
The bull case from this call is that the core lymphedema franchise is still growing strongly, with 13% revenue growth, improving referral activity, and stable Medicare dynamics after prior-authorization disruption. Management is also pointing to multiple longer-term catalysts already underway: expanded LymphaTech indication, a Flexitouch Pro filing, early payer policy wins in head and neck, and an operating model designed to improve leverage over time.
The main risk is that airway clearance remains pressured longer than expected because a concentrated group of DME customers is taking time to work through excess inventory. Management also tempered expectations for 2027, saying diagnostic adoption, reimbursement changes and payer coverage shifts will build gradually rather than produce a quick acceleration. In addition, Q4 lymphedema growth faces a tougher comparison, which could make near-term year-over-year growth look slower even if underlying momentum remains intact.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 96.7%
- Shares Outstanding
- 22.40M
- Float Shares
- 21.65M
of shares held by institutions
188 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for TCMD, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 1.92M | ▲ 18.12K |
| Morgan Stanley | 1.79M | ▲ 811.12K |
| Vanguard Group Inc | 1.65M | ▲ 76.20K |
| Cadian Capital Management, LP | 1.58M | ▲ 535.87K |
| Dimensional Fund Advisors LP | 1.13M | ▲ 37.37K |
| Vanguard Capital Management LLC | 958.51K | ▼ 11.74K |
| Driehaus Capital Management LLC | 937.78K | ▲ 195.87K |
| Acadian Asset Management LLC | 751.98K | ▼ 151.57K |
| Vanguard Portfolio Management LLC | 747.02K | ▲ 40.51K |
| Federated Hermes, Inc. | 709.70K | ▲ 28.55K |
| Arrowstreet Capital, Limited Partnership | 602.83K | ▼ 35.54K |
| State Street Corp | 596.17K | ▲ 20.03K |
Held by 194 ETFs
Biggest fund positions in TCMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | BURKE WILLIAM W | sell | 5,000 |
| Nov 4, 26 | Kiewiet Stephen A. | other | 6,438 |
| Nov 2, 26 | Kiewiet Stephen A. | other | 0 |
| Nov 3, 26 | King Laura G. | sell | 4,800 |
| Aug 10, 26 | Dodd Sheri Louise | sell | 10,978 |
| May 11, 26 | Birkemeyer Elaine M. | sell | 4,631 |
| May 6, 26 | Asbury Valerie L. | other | 6,521 |
| May 6, 26 | Huggenberger Raymond | other | 6,521 |
| May 6, 26 | King Laura G. | other | 6,521 |
| May 6, 26 | Pearson Andrea | other | 6,521 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our TCMD coverage
Recent articles, reports, and earnings notes.
No research on TCMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TCMD report →Wall Street Analysts See a 39.78% Upside in Tactile Systems Technology (TCMD): Can the Stock Really Move This High?
zacks.com · Nov 20
Tactile Medical to Participate in the Piper Sandler 38th Annual Healthcare Conference
globenewswire.com · Nov 18
Tactile Systems Technology (TCMD) Just Reclaimed the 200-Day Moving Average
zacks.com · Nov 5
Tactile Systems Technology: The Paperwork Moat Behind A Mispriced Lymphedema Franchise
seekingalpha.com · Nov 5
Wall Street Analysts Think Tactile Systems Technology (TCMD) Could Surge 52.02%: Read This Before Placing a Bet
zacks.com · Nov 4
Tactile Systems Technology (TCMD) Just Overtook the 20-Day Moving Average
zacks.com · Nov 4
Tactile Systems: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 3
Tactile Systems Technology, Inc. (TCMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.